Tekcapital Reports Record 46% Net Asset Growth and £19.2m Profit in 2024

If there’s one thing investors love more than a turnaround story, it’s a 46% net asset growth paired with a £19.2m profit swing. Tekcapital’s 2024 results aren’t just a rebound-they’re a full-throttle demonstration of how to transform university IP into real-world value. Let’s unpack why these numbers matter and what they signal for the future.

From Red to Black: A Financial Resurrection

Last year’s loss of $15.7m has been decisively flipped into a $19.2m profit-a $35m positive swing that would make even Lazarus blush. The drivers?

• 🎯 Portfolio valuation surge: Up 49.6% to $61.5m
• 📉 Cost discipline: 26% reduction in admin expenses
• 💸 IPO magic: £18.3m crystallised through MicroSalt and GenIP listings

But the real story isn’t just the numbers-it’s the velocity of value creation. With four of five portfolio companies now publicly traded, Tekcapital’s model of nurturing early-stage tech is hitting its stride.

Portfolio Powerhouses: Where the Rubber Meets the Road

This isn’t a one-hit wonder. Across Tekcapital’s stable, we’re seeing commercial traction that would make a Formula 1 team jealous:

MicroSalt (AIM: SALT)

• Secured bulk orders from a Top 5 global snack manufacturer
• 10x projected B2B volume growth for 2025
• New FDA nutrition labelling rules acting as rocket fuel

Innovative Eyewear (NASDAQ: LUCY)

• 82% YoY revenue growth in Q2
• Landmark deals with Micro Center and 600+ Canadian optometrists
• First-mover advantage in ANSI-certified smart safety glasses

Guident (Pre-IPO)

• Remote monitoring tech live in West Palm Beach shuttles
• Space Florida-backed satellite redundancy system
• NASDAQ listing quietly progressing behind the scenes

The 66% Discount Dilemma

Here’s the head-scratcher: despite stellar execution, Tekcapital trades at a 66% discount to NAV-far steeper than UK peer averages. But context is key:

Company	2024 Discount to NAV
Tekcapital	66%
Molten Ventures	52%
IP Group	45%

This gap could narrow rapidly if:

• Guident’s NASDAQ listing attracts US growth investors
• MicroSalt converts its 290MT order pipeline into revenue
• Belluscura’s strategic review unlocks medical device value

Looking Ahead: AI, Optionality, and the Dividend Dream

Management isn’t resting on laurels. The GenAI investment pivot signals smart evolution, while £2.3m MicroSalt fundraising shows appetite remains strong. That promised special dividend? Closer than you think-if 2025 monetisation events hit target.

In a market still sceptical about IP commercialisation, Tekcapital’s 2024 report card makes a compelling case: this isn’t just a portfolio-it’s a pipeline of real companies solving real problems. As Benjamin Franklin (apparently) once said: “A penny saved is two pence clear.” For Tekcapital shareholders, those pennies are now multiplying faster than rabbits in springtime.